T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
SELL

Pfizer Inc(PFE)

Feb 17, 2010
One of the mega pharmas that is having trouble getting traction because it is so large. They have a problem with one of their large drugs (25% of business) coming off patent within the next year. He would look elsewhere. J&J, Abbot, are better picks.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$17.67

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 03, 2010
Model price of $29.40, a 53% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$18.62

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 03, 2010
Just reported lower-than-expected earnings. Chart shows a strong upward trend so technically it still looks good. Usually healthcare stocks do very well from July to October.
Photo of Don VialouxDon VialouxUnlock Rating
$18.62

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 28, 2010
(A Top Pick Jan 27/09. Up 25.12%.) Likes the outlook for drug stocks. Still a Buy.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$18.63

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 14, 2010
Have their challenges with patent expiries but a huge global player with very good exposure to emerging markets. Reasonable dividend. 3.7% yield.
Photo of Jeff BlackJeff BlackUnlock Rating
$19.38

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 13, 2010
Loss of their Lipitor patent in 2011 (25% of revenues) is priced into the stock but this is a problem with all Pharma plays. Patent expirations is hugely punitive. (See Top Picks.)
Photo of Gordon ReidGordon ReidUnlock Rating
$19.21

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 23, 2009
(A Top Pick Jan 27/09. Up 17.5%.) The world hated pharmaceutical stocks but started to like them more. All the major pharmas have patents coming off in the next 5 years. This is already built into the price. Companies have all built up big cash reserves.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$18.58

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 15, 2009
Biovail is the only Canadian equivalent. He likes the industry. Concern as patents expire. Market has valued this concern into the price. Continue to generate cash flow. Prefers Merck.
Photo of Ara NalbandianAra Nalbandian
No
Unlock Rating
$18.29

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 16, 2009
US healthcare stocks were ignored until recently. Recently completed its acquisition of Wyeth, which gives them a new product pipeline. 3.7% yield.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$17.94

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 06, 2009
The issue here is Lipitor patents coming off in 2010 and they have to fill the product pipeline with something that is going to be a blockbuster. Question that they can use their cash horde effectively to fill the R&D pipeline, get new products to market and get their profits up. (See Top Picks.)
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$16.96

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 04, 2009
About the 50-day and 200-day moving averages and is continuing to climb. 3.7% dividend and they are due for an increase.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$16.93

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 27, 2009
Big pharmaceutical has 3 major problems. 1) Cost of developing new drugs keeps going up and up. 2) When you do find a new drug there are chances of killing/harming people accidentally. 3) When you do find a new drug that works, the generics come after you.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$17.26

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Oct 22, 2009
(Market Call Minute) Interesting play. They’ve just done a huge deal. Corporations that do huge take-overs usually take a while to swallow the company.
Photo of Benj GallanderBenj GallanderUnlock Rating
$17.56

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Pfizer Inc(PFE)

Oct 15, 2009
A lot of their drugs were coming off patent, which is why they bought Wyeth, which has a strong portfolio of women's healthcare. With this acquisition closing, she would expect a lot of integration savings and cutting of costs. She would like more detail on this.
Photo of Christine PooleChristine PooleUnlock Rating
$17.66

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 13, 2009
Although they have drugs coming off patent over the next few years, they are acquiring wyeth and they have some promising new drugs.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$16.78

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 466 to 480 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like